TickerHumSide-by-side comparison
AbbVie vs Bristol-Myers Squibb
As of Nov 11, 2026, P/E is 50.8x for AbbVie vs 13.9x for Bristol-Myers Squibb; P/S is 7.9x for AbbVie vs 2.6x for Bristol-Myers Squibb; revenue growth is 10.7% for AbbVie vs 4.2% for Bristol-Myers Squibb; net margin is 15.7% for AbbVie vs 18.5% for Bristol-Myers Squibb.
What stands out
- Bristol-Myers Squibb is cheaper on earnings: 13.9x P/E vs 50.8x for AbbVie.
Key metrics
| Metric | ABBV | BMY |
|---|---|---|
| Price | $294.98 | $62.91 |
| Market cap | $521.41B | $128.59B |
| P/E | 50.8x (#2) | 13.9x (#1) |
| P/S | 7.9x (#2) | 2.6x (#1) |
| Revenue growth | 10.7% (#1) | 4.2% (#2) |
| Operating margin | 32.2% (#1) | — |
| Net margin | 15.7% (#2) | 18.5% (#1) |
| Debt / equity | — | 1.79 (#1) |
| 1-year return | +26.5% (#2) | +28.2% (#1) |
| Research score | 63/100 (#2) | 69/100 (#1) |
Higher is better for growth, margins, one-year return and overall score; lower is better for valuation and debt ratios. Ties share a rank and missing values are excluded.
Company research
- AbbVie Inc. (ABBV) — Drug Manufacturers—General
- Bristol-Myers Squibb Company (BMY) — Drug Manufacturers—General